AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS

Automated Antimicrobial Susceptibility Testing Market, By Product Type (Consumables and Instruments), By Detection Method (Turbidimetric and Colorimetric), By Application (Antibacterial (Tuberculosis and Sepsis), Antifungal, Anti-parasitic, and Anti-viral), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals, and Pathology/Diagnostic Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Published In : May 2019
Code : CMI2622
Pages :200
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market News

Increasing number of multidrug resistance cases in tuberculosis (TB), malaria, HIV, influenza, and others among the global population is expected to result in increasing adoption of antimicrobial susceptibility testing to reduce the resistance exposure during the forecast period. For instance, according to the World Health Organization (WHO), in 2014, there were around 480,000 new cases of multidrug-resistant tuberculosis (MDR-TB), a form of tuberculosis that is resistant to the two most powerful anti-TB drugs. Among these, only around 123,000 cases were detected and reported.

Moreover, increasing number of product launches is also expected to highly contribute to the automated antimicrobial susceptibility testing market growth. For instance, in March 2016, Becton, Dickinson and Company launched the new BD Phoenix M50 ID/AST system, which helps to deliver the same rapid, accurate, and cost-effective testing as the legacy BD Phoenix 100, within a small footprint.